MesoPher

BIOLOGICAL3 trials

Sponsors

Amphera BV, Erasmus Medical Center, Joachim Aerts, MD PhD

Conditions

MesotheliomaMesotheliomas PleuralMetastatic Pancreatic Cancer

Phase 1

dENdritic Cell Therapy Combined With SURgEry in Mesothelioma

RecruitingNCT05304208

Erasmus Medical CenterMesotheliomas Pleural

Start: 2021-11-02End: 2026-12-31Target: 16Updated: 2025-04-25

MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

CompletedNCT05650918

Joachim Aerts, MD PhDMetastatic Pancreatic Cancer

Start: 2021-08-30End: 2023-05-23Updated: 2023-10-12

Phase 2

DENdritic Cell Immunotherapy for Mesothelioma

CompletedNCT03610360

Amphera BVMesothelioma

Start: 2018-06-21End: 2022-06-30Updated: 2024-02-01

Related Papers

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

2025-11-281 citations

Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.

2024-06-0412 citations

Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.

Journal of Clinical Oncology2021-05-20